Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia

Neuropsychopharmacology

Volumn 37, Issue 1, 2012, Pages 16-42

  Jones, Carrie K ^a   Byun, Nellie ^a,b   Bubser, Michael ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

acetylcholine; drug discovery and drug development; schizophrenia; schizophrenia and antipsychotics

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID C RECEPTOR; AMPHETAMINE; BUNGAROTOXIN RECEPTOR; CLOZAPINE; DOPAMINE; G PROTEIN COUPLED RECEPTOR; HALOPERIDOL; LY2033298; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MUSCARINIC AGENT; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC M5 RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; NICOTINIC AGENT; NICOTINIC RECEPTOR ALPHA4BETA2; UNCLASSIFIED DRUG; VU0029767; VU0090157; XANOMELINE;

AGRANULOCYTOSIS; ALLOSTERISM; ALZHEIMER DISEASE; ANXIETY DISORDER; BRAIN CORTEX; CATALEPSY; CHOLINERGIC TRANSMISSION; CIGARETTE SMOKING; COGNITION; COGNITIVE DEFECT; CORPUS STRIATUM; DEMENTIA; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DOPAMINERGIC SYSTEM; DRUG ACTIVITY; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; FOREBRAIN; GASTROINTESTINAL DISEASE; GENE DELETION; GENE LOCUS; HIPPOCAMPUS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; LOCOMOTION; METABOLIC SYNDROME X; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SUBSTANTIA NIGRA;

ALLOSTERIC REGULATION; DRUG DESIGN; HUMANS; MUSCARINIC AGONISTS; NICOTINIC AGONISTS; SCHIZOPHRENIA;

EID: 84856079359     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2011.199     Document Type: Review

References (327)

1. Abrams P, Andersson KE, Buccafusco JJ, Chapple C, de Groat WC, Fryer AD et al (2006). Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 48: 565-578. (Pubitemid 43993048)
2. Adler LE, Hoffer LJ, Griffith J, Waldo MC, Freedman R (1992). Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol Psychiatry 32: 607-616.
3. Adler LE, Hoffer LJ, Wiser A, Freedman R. (1993). Cigarette smoking normalizes auditory physiology in schizophrenics. Am J Psychiatry 150: 1856-1861. (Pubitemid 23356580)
4. Agid O, Kapur S, Arenovich T, Zipursky RB (2003). Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 60: 1228-1235. (Pubitemid 37494076)
5. Agid O, Kaour S, Warrington L, Loebel A, Siu C (2008). Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disorders. Schizophr Res 102: 241-248.
6. AhnAllen CG, Nestor PG, Shenton ME, McCarley RW, Niznikiewicz MA (2008). Early nicotine withdrawal and transdermal nicotine effects on neurocognitive performance in schizophrenia. Schizophr Res 100: 261-269. (Pubitemid 351324859)
7. Aigner TG, Mishkin M (1986). The effects of physostigmine and scopolamine on recognition memory in monkeys. Behav Neural Biol 45: 81-87. (Pubitemid 16162297)
8. Albuquerque EX, Pereira EF, Alkondon M, Rogers SW (2009). Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev 89: 73-120.
9. American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Publishing: Washington, DC.
10. Anagnostaras SG, Murphy GG, Hamilton SE, Mitchell SL, Rahnama NP, Nathanson NM et al (2003). Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci 6: 51-58. (Pubitemid 36026332)
11. Andersen MB, Fink-Jensen A, Peacock L, Gerlach J, Bymaster F, Lundbaek JA et al (2003). The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys. Neuropsychopharmacology 28: 1168-1175.
12. Anderson DJ, Malysz J, Gr̈nlien JH, El Kouhen R, Hakerud M, Wetterstrand C et al (2009). Stimulation of dopamine release by nicotinic acetylcholine receptor ligands in rat brain slices correlates with the profile of high, but not low, sensitivity alpha4beta2 subunit combination. Biochem Pharmacol 78: 844-851.
13. Araya R, Noguchi T, Yuhki M, Kitamura N, Higuchi M, Saido TC et al (2006). Loss of M5 muscarinic acetylcholine receptors leads to cerebrovascular and neuronal abnormalities and cognitive deficits in mice. Neurobiol Dis 24: 334-344. (Pubitemid 44572752)
14. Arneric SP, Sullivan JP, Briggs CA, Donnelly-Roberts D, Anderson DJ, Raszkiewicz JL et al (1994). (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterization. J Pharmacol Exp Ther 270: 310-318. (Pubitemid 24229641)
15. Avila MT, Sherr JD, Hong E, Myers CS, Thaker GK (2003). Effects of nicotine on leading saccades during smooth pursuit eye movements in smokers and nonsmokers with schizophrenia. Neuropsychopharmacology 28: 2184-2191. (Pubitemid 37468186)
16. Avlani VA, Langmead CJ, Guida E, Wood MD, Tehan BG, Herdon HJ et al (2010). Orthosteric and allosteric modes of interaction of novel selective agonists of the M1 muscarinic acetylcholine receptor. Mol Pharmacol 78: 94-104.
17. Barak S, Arad M, De Levie A, Black MD, Griebel G, Weiner I (2009). Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia. Neuropsychopharmacology 34: 1753-1763.
18. Barr RS, Culhane MA, Jubelt LE, Mufti RS, Dyer MA, Weiss AP et al (2008). The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology 33: 480-490.
19. Basile AS, Fedorova I, Zapata A, Liu XG, Shippenberg T, Duttaroy A et al (2002). Deletion of the M5 muscarinic acetylcholine receptor attenuates morphine reinforcement and withdrawal but not morphine analgesia. Proc Natl Acad Sci USA 99: 11452-11457. (Pubitemid 34920946)
20. Beneyto M, Lewis DA (2011). Insights into the neurodevelopmental origin of schizophrenia from postmortem studies of prefrontal cortical circuitry. Int J Dev Neurosci 29: 295-304.
21. Benowitz NL (1988). Toxicity of nicotine: implications with regard to nicotine replacement therapy. Prog Clin Biol Res 261: 187-217.
22. Benowitz NL, Gourlay SG (1997). Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. J Am Coll Cardiol 29: 1422-1431. (Pubitemid 27272432)
23. Bird ED, Spokes EG, Barnes J, MacKay AV, Iversen LL, Shepherd M (1977). Increased brain dopamine and reduced glutamic acid decarboxylase and choline acetyl transferase activity in schizophrenia and related psychoses. Lancet 2: 1157-1158.
24. Bitner RS, Bunnelle WH, Anderson DJ, Briggs CA, Buccafusco J, Curzon P et al (2007). Broad-spectrum efficacy across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways. J Neurosci 27: 10578-10587. (Pubitemid 47502013)
25. Biton B, Bergis OE, Galli F, Nedelec A, Lochead AW, Jegham S et al (2007). SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile. Neuropsychopharmacology 32: 1-16. (Pubitemid 44967780)
26. Blondel A, Sanger DJ, Moser PC (2000). Characterisation of the effects of nicotine in the five-choice serial reaction time task in rats: antagonist studies. Psychopharmacology 149: 293-305. (Pubitemid 30262344)
27. Blount P, Merlie JP (1989). Molecular basis of the two nonequivalent ligand binding sites of the muscle nicotinic acetylcholine receptor. Neuron 3: 349-357.
28. Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A et al (1997a). Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 54: 465-473. (Pubitemid 27172867)
29. Bodick NC, Offen WW, Shannon HE, Satterwhite J, Lucas R, van Lier R et al (1997b). The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease. Alzheimer Dis Assoc Disord 11(Suppl 4): S16-S22. (Pubitemid 27453885)
30. Boess FG, De Vry J, Erb C, Flessner T, Hendrix M, Luithle J et al (2007). The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents. J Pharmacol Exp Ther 321: 716-725. (Pubitemid 46624485)
31. Bolam JP, Wainer BH, Smith AD (1984). Characterization of cholinergic neurons in the rat neostriatum: a combination of choline acetyltransferase immunocytochemistry, golgi-impregnation and electron microscopy. Neuroscience 12: 711-718. (Pubitemid 14092487)
32. Bonner TI, Buckley NJ, Young AC, Brann MR (1987). Identification of a family of muscarinic acetylcholine receptor genes. Science 237: 527-532. (Pubitemid 17125922)
33. Bonner TI, Young AC, Brann MR, Buckley NJ (1988). Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes. Neuron 1: 403-410.
34. Bradley SR, Lameh J, Ohrmund L, Son T, Bajpai A, Nguyen D et al (2010). AC-260584, an orally bioavailable M(1) muscarinic receptor allosteric agonist, improves cognitive performance in an animal model. Neuropharmacology 58: 365-373.
35. Brady AE, Jones CK, Bridges TM, Kennedy JP, Thompson AD, Heiman JU et al (2008). Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats. J Pharmacol Exp Ther 327: 941-953.
36. Breese CR, Lee MJ, Adams CE, Sullivan B, Logel J, Gillen KM et al (2000). Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology 23: 351-364.
37. Breese CR, Marks MJ, Logel J, Adams CE, Sullivan B, Collins AC et al (1997). Effect of smoking history on [3H]nicotine binding in human postmortem brain. J Pharmacol Exp Ther 282: 7-13. (Pubitemid 27425521)
38. Bridges TM, Kennedy JP, Hopkins CR, Conn PJ, Lindsley CW (2010). Heterobiaryl and heterobiaryl ether derived M5 positive allosteric modulators. Bioorg Med Chem Lett 20: 5617-5622.
39. Bridges TM, Marlo JE, Niswender CM, Jones CK, Jadhav SB, Gentry PR et al (2009). Discovery of the first highly M5-preferring muscarinic acetylcholine receptor ligand, an M5 positive allosteric modulator derived from a series of 5-trifluoromethoxy N-benzyl isatins. J Med Chem 52: 3445-3448.
40. Briggs CA, Anderson DJ, Brioni JD, Buccafusco JJ, Buckley MJ, Campbell JE et al (1997). Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo. Pharmacol Biochem Behav 57: 231-241. (Pubitemid 27261416)
41. Bruno G, Mohr E, Gillespie M, Fedio P, Chase TN (1986). Muscarinic agonist therapy of Alzheimer's disease. A clinical trial of RS-86. Arch Neurol 43: 659-661. (Pubitemid 16098014)
42. Buccafusco JJ, Beach JW, Terry Jr AV (2009). Desensitization of nicotinic acetylcholine receptors as a strategy for drug development. J Pharmacol Exp Ther 328: 364-370.
43. Buccafusco JJ, Jackson WJ (1991). Beneficial effects of nicotine administered prior to a delayed matching-to-sample task in young and aged monkeys. Neurobiol Aging 12: 233-238.
44. Buccafusco JJ, Jackson WJ, Terry Jr AV, Marsh KC, Decker MW, Arneric SP (1995). Improvement in performance of a delayed matching-to-sample task by monkeys following ABT-418: a novel cholinergic channel activator for memory enhancement. Psychopharmacology 120: 256-266.
45. Buccafusco JJ, Terry Jr AV (2009). A reversible model of the cognitive impairment associated with schizophrenia in monkeys: potential therapeutic effects of two nicotinic acetylcholine receptor agonists. Biochem Pharmacol 78: 852-862.
46. Buccafusco JJ, Terry Jr AV, Decker MW, Gopalakrishnan M (2007). Profile of nicotinic acetylcholine receptor agonists ABT-594 and A-582941, with differential subtype selectivity, on delayed matching accuracy by young monkeys. Biochem Pharmacol 74: 1202-1211. (Pubitemid 47417930)
47. Buchanan KA, Petrovic MM, Chamberlain SE, Marrion NV, Mellor JR (2010). Facilitation of long-term potentiation by muscarinic M(1) receptors is mediated by inhibition of SK channels. Neuron 68: 948-963.
48. Bustillo JR, Lauriello J, Rowland LM, Thomson LM, Petropoulos H, Hammond R et al (2002). Longitudinal follow-up of neurochemical changes during the first year of antipsychotic treatment in schizophrenia patients with minimal previous medication exposure. Schizophr Res 58: 313-321. (Pubitemid 35284523)
49. Bymaster FP, Heath I, Hendrix JC, Shannon HE (1993). Comparative behavioral and neurochemical activities of cholinergic antagonists in rats. J Pharmacol Exp Ther 267: 16-24. (Pubitemid 23324983)
50. Byun N, Lawson K, Gore JC, Conn PJ, Jones CK (2011). Antipsychotic-like profile and reversal of cognitive impairment with the positive allosteric modular of the M4 muscarinic acetylcholine receptor VU0152100. Abstracts of the 13th International Congress on Schizophrenia Research (ICOSR). Schizophr Bull Suppl 1: 1-342.
51. Campo-Arias A, D́az-Mart́nez LA, Rueda-Jaimes GE, Rueda-Sánchez M, Farelo-Palaćn D, Diaz FJ et al (2006). Smoking is associated with schizophrenia, but not with mood disorders, within a population with low smoking rates: a matched case-control study in Bucaramanga, Colombia. Schizophr Res 83: 269-276.
52. Carbone AL, Moroni M, Groot-Kormelink PJ, Bermudez I (2009). Pentameric concatenated (alpha4)(2)(beta2)(3) and (alpha4)(3)(beta2)(2) nicotinic acetylcholine receptors: subunit arrangement determines functional expression. Br J Pharmacol 156: 970-981.
53. Carey GJ, Billard W, Binch 3rd H, Cohen-Williams M, Crosby G, Grzelak M et al (2001). SCH 57790, a selective muscarinic M(2) receptor antagonist, releases acetylcholine and produces cognitive enhancement in laboratory animals. Eur J Pharmacol 431: 189-200. (Pubitemid 33132125)
54. Carlsson A (1977). Does dopamine play a role in schizophrenia? Psychol Med 7: 583-597. (Pubitemid 8232990)
55. Castner SA, Smagin GN, Piser TM, Wang Y, Smith JS, Christian EP et al (2011). Immediate and sustained improvements in working memory after selective stimulation of a7 nicotinic acetylcholine receptors. Biol Psychiatry 69: 12-18.
56. Chambon C, Wegener N, Gravius A, Danysz W (2011). A new automated method to assess the rat recognition memory: validation of the method. Behav Brain Res 222: 151-157.
57. Chan WK, Wong PT, Sheu FS (2007). Frontal cortical alpha7 and alpha4beta2 nicotinic acetylcholine receptors in working and reference memory. Neuropharmacology 52: 1641-1649. (Pubitemid 46843139)
58. Chan WY, McKinzie DL, Bose S, Mitchell SN, Witkin JM, Thompson RC et al (2008). Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia. Proc Natl Acad Sci USA 105: 10978-10983.
59. Changeux JP, Devillers-Thiéry A, Chemouilli P (1984). Acetylcholine receptor: an allosteric protein. Science 225: 1335-1345. (Pubitemid 14026339)
60. Christopoulos A, Mitchelson F (1997). Application of an allosteric ternary complex model to the technique of pharmacological resultant analysis. J Pharm Pharmacol 49: 781-786. (Pubitemid 27386900)
61. Conn PJ, Christopoulos A, Lindsley CW (2009). Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov 8: 41-54.
62. Conti-Tronconi BM, Hunkapiller MW, Lindstrom JM, Raftery A (1982). Subunit structure of the acetylcholine receptor from electrophorus electricus. Proc Natl Acad Sci USA 79: 6489-6493. (Pubitemid 13207520)
63. Corriveau RA, Berg DK (1993). Coexpression of multiple acetylcholine receptor genes in neurons: quantification of transcripts during development. J Neurosci 13: 2662-2671. (Pubitemid 23151780)
64. Costa E, Auta J, Caruncho H, Guidotti A, Impagnatiello F, Pesold C et al (1995). A search for a new anticonvulsant and anxiolytic benzodiazepine devoid of side effects and tolerance liability. Adv Biochem Psychopharmacol 48: 75-92.
65. Court J, Spurden D, Lloyd S, McKeith I, Ballard C, Cairns N et al (1999). Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: alphabungarotoxin and nicotine binding in the thalamus. J Neurochem 73: 1590-1597. (Pubitemid 29440161)
66. Court JA, Lloyd S, Thomas N, Piggott MA, Marshall EF, Morris CM et al (1998). Dopamine and nicotinic receptor binding and the levels of dopamine and homovanillic acid in human brain related to tobacco use. Neuroscience 87: 63-78. (Pubitemid 28351169)
67. Crook JM, Dean B, Pavey G, Copolov D (1999). The binding of [3H]AF-DX 384 is reduced in the caudate-putamen of subjects with schizophrenia. Life Sci 64: 1761-1771. (Pubitemid 29185535)
68. Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B (2000). Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol Psychiatry 48: 381-388.
69. Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B (2001). Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. Am J Psychiatry 158: 918-925. (Pubitemid 32547622)
70. Dajas-Bailador FA, Mogg AJ, Wonnacott S (2002). Intracellular Ca2+ signals evoked by stimulation of nicotinic acetylcholine receptors in SH-SY5Y cells: contribution of voltage-operated Ca2+ channels and Ca2+ stores. J Neurochem 81: 606-614. (Pubitemid 34809339)
71. Dean B, Crook JM, Opeskin K, Hill C, Keks N, Copolov DL (1996). The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia. Mol Psychiatry 1: 54-58. (Pubitemid 126442395)
72. Dean B, McLeod M, Keriakous D, McKenzie J, Scarr E (2002). Decreased muscarinic(1) receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry 7: 1083-1091. (Pubitemid 36044267)
73. Decker MW, Bannon AW, Curzon P, Gunther KL, Brioni JD, Holladay MW et al (1997). ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride]: II. A novel cholinergic channel modulator with effects on cognitive performance in rats and monkeys. J Pharmacol Exp Ther 283: 247-258. (Pubitemid 27438968)
74. Decker MW, Brioni JD, Sullivan JP, Buckley MJ, Radek RJ, Raszkiewicz JL et al (1994a). (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization. J Pharmacol Exp Ther 270: 319-328. (Pubitemid 24229642)
75. Decker MW, Curzon P, Brioni JD, ArnerićSP (1994b). Effects of ABT-418, a novel cholinergic channel ligand, on place learning in septal-lesioned rats. Eur J Pharmacol 261: 217-222. (Pubitemid 24263225)
76. Decker MW, Majchrzak MJ (1992). Effects of systemic and intracerebroventricular administration of mecamylamine, a nicotinic cholinergic antagonist, on spatial memory in rats. Psychopharmacology 107: 530-534.
77. De Leon J, Dadvand M, Canuso C, White AO, Stanilla JK, Simpson GM (1995). Schizophrenia and smoking: an epidemiological survey in astate hospital. Am J Psychiatry 152: 453-455.
78. De Leon J, Diaz FJ, Rogers T, Browne D, Dinsmore L (2002). Initiation of daily smoking and nicotine dependence in schizophrenia and mood disorders. Schizophr Res 56: 47-54. (Pubitemid 34655467)
79. De Luca V, Voineskos S, Wong G, Kennedy JL (2006). Genetic interaction between a4 and b2 of high affinity nicotinic receptor: analysis in schizophrenia. Exp Brain Res 174: 292-296. (Pubitemid 44421106)
80. De Luca V, Wang H, Squassina A, Wong GW, Yeomans J, Kennedy JL (2004). Linkage of M5 muscarinic and alpha7-nicotinic receptor genes on 15q13 to schizophrenia. Neuropsychobiology 50: 124-127. (Pubitemid 39077830)
81. Deng C, Huang XF (2005). Decreased density of muscarinic receptors in the superior temporal gyrus in schizophrenia. J Neurosci Res 81: 883-890. (Pubitemid 41532154)
82. Digby GJ, Conn PJ, Lindsley CW (2010). Orthosteric-and allosteric-induced liganddirected trafficking at GPCRs. Curr Opin Drug Discov Dev 13: 587-594.
83. Domer FR, Schueler FW (1960). Investigations of the amnesic properties of scopolamine and related compounds. Arch Int Pharmacodyn Ther 127: 449-458.
84. Domino EF, Mohrman ME, Wilson AE, Haarstad VB (1973). Acetylseco hemicholinium-3, a new choline acetyltransferase inhibitor useful in neuropharmacological studies. Neuropharmacology 12: 549-561.
85. Dunbar G, Kuchibhatla R, Lee G (2011). A randomized double-blind study comparing 25 and 50mg TC-1734 (AZD3480) with placebo, in order subjects with age-associated memory impairment. J Psychopharmacol 25: 1020-1029.
86. Dutar P, Nicoll RA (1988). Classification of muscarinic responses in hippocampus in terms of receptor subtypes and second-messenger systems: electrophysiological studies in vitro. J Neurosci 8: 4214-4224. (Pubitemid 19017404)
87. Edelstein P, Schultz JR, Hirschowitz J, Kanter DR, Garver DL (1981). Physostigmine and lithium in the schizophrenias. Am J Psychiatry 138: 1078-1081.
88. Ehlert FJ, Roeske WR, Gee KW, Yamamura HI (1983). An allosteric model for benzodiazepine receptor function. Biochem Pharmacol 32: 2375-2383. (Pubitemid 13049296)
89. Elrod K, Buccafusco JJ, Jackson WJ (1988). Nicotine enhances delayed matchingto-sample performance by primates. Life Sci 43: 277-287.
90. Erwin RJ, Turetsky BI, Moberg P, Gur RC, Gur RE (1998). P50 abnormalities in schizophrenia: relationship to clinical and neuropsychological indices of attention. Schizophr Res 33: 157-167. (Pubitemid 28446540)
91. Espada S, Rojo AI, Salinas M, Cuadrado A (2009). The muscarinic M1 receptor activates Nrf2 through a signaling cascade that involves protein kinase C and inhibition of GSK-3beta: connecting neurotransmission with neuroprotection. J Neurochem 110: 1107-1119.
92. Fabian-Fine R, Skehel P, Errington ML, Davies HA, Sher E, Stewart MG et al (2001). Ultrastructural distribution of the alpha7 nicotinic acetylcholine receptor subunit in rat hippocampus. J Neurosci 21: 7993-8003. (Pubitemid 32952756)
93. Faghih R, Gopalakrishnan SM, Gronlien JH, Malysz J, Briggs CA, Wetterstrand C et al (2009). Discovery of 4-(5-(4-chlorophenyl)-2-methyl-3- propionyl-1H-pyrrol-1-yl)benzenesulfonamide (A-867744) as a novel positive allosteric modulator of the alpha7 nicotinic acetylcholine receptor. J Med Chem 52: 3377-3384.
94. Felder CC (1995). Muscarinic acetylcholine receptors: signal transduction through multiple effectors. FASEB J 9: 619-625.
95. Feldman HH, Ferris S, Winblad B, Sfikas N, Mancione L, He Y et al (2007). Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol 6: 501-512. (Pubitemid 46738627)
96. Fenster CP, Rains MF, Noerager B, Quick MW, Lester RA (1997). Influence of subunit composition on desensitization of neuronal acetylcholine receptors at low concentrations of nicotine. J Neurosci 17: 5747-5759. (Pubitemid 27310490)
97. Feuerbach D, Lingenhoehl K, Olpe HR, Vassout A, Gentsch C, Chaperon F et al (2009). The selective nicotinic acetylcholine receptor alpha7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain. Neuropharmacology 56: 254-263.
98. File SE (1985). Tolerance to the behavioral actions of benzodiazepines. Neurosci Biobehav Rev 9: 113-121. (Pubitemid 15136676)
99. Fink-Jensen A, Fedorova I, Wörtwein G, Woldbye DP, Rasmussen T, Thomsen M et al (2003). Role for M5 muscarinic acetylcholine receptors in cocaine addiction. J Neurosci Res 74: 91-96. (Pubitemid 37176671)
100. Forette F, Anand R, Gharabawi G (1999). A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon). Eur J Neurol 6: 423-429. (Pubitemid 29371138)
101. Freedman R, Coon H, Myles-Worsley M, Orr-Urtreger A, Olincy A, Davis A et al (1997). Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci USA 94: 587-592. (Pubitemid 27053677)
102. Freedman R, Hall M, Adler LE, Leonard S (1995). Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 38: 22-33.
103. Freedman R, Leonard S, Gault JM, Hopkins J, Cloninger CR, Kaufmann CA et al (2001). Linkage disequilibrium for schizophrenia at the chromosome 15q13-14 locus of the alpha7-nicotinic acetylcholine receptor subunit gene (CHRNA7). Am J Med Genet 105: 20-22.
104. Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, Johnson L et al (2008). Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 165: 1040-1047.
105. Garver DL, Bissette G, Yao JK, Nemeroff CB (1991). Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients. Am J Psychiatry 148: 484-488.
106. George TP, Termine A, Sacco KA, Allen TM, Reutenauer E, Vessicchio JC et al (2006). A preliminary study of the effects of cigarette smoking on prepulse inhibition in schizophrenia: involvement of nicotinic receptor mechanisms. Schizophr Res 87: 307-315. (Pubitemid 44462734)
107. Gerber DJ, Sotnikova TD, Gainetdinov RR, Huang SY, Caron MG, Tonegawa S (2001). Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in Ml muscarinic acetylcholine receptor-deficient mice. Proc Natl Acad Sci USA 98: 15312-15317. (Pubitemid 34014011)
108. Gerlach J, Thorsen K, Fog R (1975). Extrapyramidal reactions and amine metabolites in cerebrospinal fluid during haloperidol and clozapine treatment of schizophrenic patients. Psychopharmacologia 40: 341-350.
109. Gomeza J, Shannon H, Kostenis E, Felder C, Zhang L, Brodkin J et al (1999b). Pronounced pharmacologic deficits in M2 muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci USA 96: 1692-1697. (Pubitemid 29098513)
110. Gomeza J, Zhang L, Kostenis E, Felder C, Bymaster F, Brodkin J et al (1999a). Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci USA 96: 10483-10488. (Pubitemid 29422585)
111. Gopalakrishnan M, Molinari EJ, Sullivan JP (1997). Regulation of human a4b2 neuronal nicotinic acetylcholine receptors by cholinergic channel ligands and second messenger pathways. Mol Pharmacol 52: 524-534. (Pubitemid 27412979)
112. Gotti C, Clementi F (2004). Neuronal nicotinic receptors: from structure to pathology. Prog Neurobiol 74: 363-396. (Pubitemid 40092737)
113. Green MF, Kern RS, Heaton RK (2004). Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res 72: 41-51. (Pubitemid 39452904)
114. Griffith JM, O'Neill JE, Petty F, Garver D, Young D, Freedman R (1998). Nicotinic receptor desensitization and sensory gating deficits in schizophrenia. Biol Psychiatry 44: 98-106. (Pubitemid 28305528)
115. Gronlien JH, Hakerud M, Ween H, Thorin-Hagene K, Briggs CA, Gopalakrishnan M et al (2007). Distinct profiles of alpha7 nAChR positive allosteric modulation revealed by structurally diverse chemotypes. Mol Pharmacol 72: 715-724. (Pubitemid 47347306)
116. Grottick AJ, Haman M, Wyler R, Higgins GA (2003). Reversal of a vigilance decrement in the aged rat by subtype-selective nicotinic ligands. Neuropsychopharmacology 28: 880-887.
117. Grottick AJ, Higgins GA (2000). Effect of subtype selective nicotinic compounds on attention as assessed by the five-choice serial reaction time task. Behav Brain Res 117: 197-208.
118. Grottick AJ, Trube G, Corrigall WA, Huwyler J, Malherbe P, Wyler R et al (2000). Evidence that nicotinic alpha(7) receptors are not involved in the hyperlocomotor and rewarding effects of nicotine. J Pharmacol Exp Ther 294: 1112-1119. (Pubitemid 30666867)
119. Guan ZZ, Zhang X, Blennow K, Nordberg A (1999). Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain. Neuroreport 10: 1779-1782. (Pubitemid 29354310)
120. Hahn B, Sharples CG, Wonnacott S, Shoaib M, Stolerman IP (2003). Attentional effects of nicotinic agonists in rats. Neuropharmacology 44: 1054-1067. (Pubitemid 36570430)
121. Hamborg-Petersen B, Nielsen MM, Thordal C (1984). Toxic effect of scopolamine eye drops in children. Acta Ophthalmol 62: 485-488. (Pubitemid 14100951)
122. Hansen HH, Timmermann DB, Peters D, Walters C, Damaj MI, Mikkelsen JD (2007). Alpha-7 nicotinic acetylcholine receptor agonists selectively activate limbic regions of the rat forebrain: an effect similar to antipsychotics. J Neurosci Res 85: 1810-1818. (Pubitemid 46849628)
123. Harington M, Kincaid-Smith P (1958). Psychosis and tremor due to mecamylamine. Lancet 271: 499-501.
124. Harris JG, Kongs S, Allensworth D, Martin L, Tregellas J, Sullivan B et al (2004). Effects of nicotine on cognitive deficits in schizophrenia. Neuropsychopharmacology 29: 1378-1385. (Pubitemid 38780661)
125. Harvey AL, Dryden WF (1974). Studies on the pharmacology of skeletal muscle in culture: site of action of nicotinic agonists. Eur J Pharmacol 28: 131-134.
126. Hashimoto K, Ishima T, Fujita Y, Matsuo M, Kobashi T, Takahagi M et al (2008). Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective alpha7 nicotinic receptor agonist SSR180711. Biol Psychiatry 63: 92-97. (Pubitemid 350234890)
127. Hasselmo ME, Sarter M (2010). Modes and models of forebrain cholinergic neuromodulation of cognition. Neuropsychopharmacology 36: 52-73.
128. Hauser TA, Kucinski A, Jordan KG, Gatto GJ, Wersinger SR, Hesse RA et al (2009). TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia. Biochem Pharmacol 78: 803-812.
129. Heinrich JN, Butera JA, Carrick T, Kramer A, Kowal D, Lock T et al (2009). Pharmacological comparison of muscarinic ligands: historical vs more recent muscarinic M1-preferring receptor agonists. Eur J Pharmacol 605: 53-56.
130. Hersch SM, Gutekunst CA, Rees HD, Heilman CJ, Levey AI (1994). Distribution of m1-m4 muscarinic receptor proteins in the rat striatum: light and electron microscopic immunocytochemistry using subtype-specific antibodies. J Neurosci 14: 3351-3363. (Pubitemid 24139017)
131. Howes OD, Kapur S (2009). The dopamine hypothesis of schizophrenia: version IIIFthe final common pathway. Schizophr Bull 35: 549-562.
132. Hu M, Gopalakrishnan M, Li J (2009). Positive allosteric modulation of alpha7 neuronal nicotinic acetylcholine receptors: lack of cytotoxicity in PC12 cells and rat primary cortical neurons. Br J Pharmacol 158: 1857-1864.
133. Hurst RS, Hajos M, Raggenbass M, Wall TM, Higdon NR, Lawson JA et al (2005). A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization. J Neurosci 25: 4396-4405. (Pubitemid 40628784)
134. Ince E, Ciliax BJ, Levey AI (1997). Differential expression of D1 and D2 dopamine and m4 muscarinic acetylcholine receptor proteins in identified striatonigral neurons. Synapse 27: 357-366. (Pubitemid 27479473)
135. Ingram JR, Rhodes J, Evans BK, Thomas GA (2005). Preliminary observations of oral nicotine therapy for inflammatory bowel disease: an open-label phase I-II study of tolerance. Inflamm Bowel Dis 11: 1092-1096. (Pubitemid 41682566)
136. Izzo AA, Mascolo N, Di Carlo G, Capasso F (1999). Ascending neural pathways in the isolated guinea-pig ileum: effect of muscarinic M1, M2 and M3 cholinergic antagonists. Neuroscience 91: 1575-1580. (Pubitemid 29234283)
137. Jacobson MA, Kreatsoulas C, Pascarella DM, O'Brien JA, Sur C (2010). The M1 muscarinic receptor allosteric agonists AC-42 and 1-[10-(2-methylbenzyl)-1, 40-bipiperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one bind to a unique site distinct from the acetylcholine orthosteric site. Mol Pharmacol 78: 648-657.
138. Janowsky DS, el-Yousef MK, Davis JM, Sekerke HJ (1973). Antagonistic effects of physostigmine and methylphenidate in man. Am J Psychiatry 130: 1370137-1370136.
139. Jentsch JD, Roth RH (1999). The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20: 201-225. (Pubitemid 29067401)
140. Jeon J, Dencker D, Wörtwein G, Woldbye DP, Cui Y, Davis AA et al (2010). A subpopulation of neuronal M4 muscarinic acetylcholine receptors plays a critical role in modulating dopamine-dependent behaviors. J Neurosci 30: 2396-2405.
141. Ji D, Dani JA (2000). Inhibition and disinhibition of pyramidal neurons by activation of nicotinic receptors on hippocampal interneurons. J Neurophysiol 83: 2682-2690. (Pubitemid 30321461)
142. Ji D, Lape R, Dani JA (2001). Timing and location of nicotinic activity enhances or depresses hippocampal synaptic plasticity. Neuron 31: 131-141. (Pubitemid 32757094)
143. Jo J, Son GH, Winters BL, Kim MJ, Whitcomb DJ, Dickinson BA et al (2010). Muscarinic receptors induce LTD of NMDAR EPSCs via a mechanism involving hippocalcin, AP2 and PSD-95. Nat Neurosci 13: 1216-1224.
144. Jones CK, Brady AE, Davis AA, Xiang Z, Bubser M, Tantawy MN et al (2008). Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. J Neurosci 28: 10422-10433.
145. Jones CK, Eberle EL, Shaw DB, McKinzie DL, Shannon HE (2005). Pharmacologic interactions between the muscarinic cholinergic and dopaminergic systems in the modulation of prepulse inhibition in rats. J Pharmacol Exp Ther 312: 1055-1063. (Pubitemid 40293764)
146. Jubelt LE, Barr RS, Goff DC, Logvinenko T, Weiss AP, Evins AE (2008). Effects of transdermal nicotine on episodic memory in non-smokers with and without schizophrenia. Psychopharmacology 199: 89-98.
147. Kaplan MJ, Lazoff M, Kelly K, Lukin R, Garver DL (1990). Enlargement of cerebral third ventricle in psychotic patients with delayed response to neuroleptics. Biol Psychiatry 27: 205-214. (Pubitemid 20033768)
148. Kapur S, Arenovich T, Agid O, Zipurski R, Lindborg S, Jones B (2005). Evidence for onset of antipsychotic effects within the first 24 h of treatment. Am J Psychiatry 162: 939-946. (Pubitemid 40676207)
149. Karson CN, Casanova MF, Kleinman JE, Griffin WS (1993). Choline acetyltransferase in schizophrenia. Am J Psychiatry 50: 454-459. (Pubitemid 23072472)
150. Karson CN, Mrak RE, Husain MM, Griffin WS (1996). Decreased mesopontine choline acetyltransferase levels in schizophrenia. Correlations with cognitive functions. Mol Chem Neuropathol 29: 181-191. (Pubitemid 27016928)
151. Katerina Z, Andrew K, Filomena M, Xu-Feng H (2004). Investigation of m1/m4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder. Neuropsychopharmacology 29: 619-625. (Pubitemid 38365940)
152. Keefe RS, Sweeney JA, Gu H, Hamer RM, Perkins DO, McEvoy JP et al (2007). Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 164: 1061-1071. (Pubitemid 47121395)
153. Kenakin T (2008). Functional selectivity in GPCR modulator screening. Comb Chem High Throughput Screen 11: 337-343. (Pubitemid 351830304)
154. Kenney JW, Wilkinson DS, Gould TJ (2010). The enhancement of contextual fear conditioning by ABT-418. Behav Pharmacol 21: 246-249.
155. Kimura H, McGeer PL, Peng F, McGeer EG (1980). Choline acetyltransferasecontaining neurons in rodent brain demonstrated by immunohistochemistry. Science 208: 1057-1059. (Pubitemid 10052435)
156. Kirrane RM, Mitropoulou V, Nunn M, Silverman J, Siever LJ (2001). Physostigmine and cognition in schizotypal personality disorder. Schizophr Res 48: 1-5. (Pubitemid 32241178)
157. Kishi T, Ikeda M, Kitajima T, Yamanouchi Y, Kinoshita Y, Kawashima K et al (2008). Genetic association analysis of tagging SNPs in alpha4 and beta2 subunits of neuronal nicotinic acetylcholine receptor genes (CHRNA4 and CHRNB2) with schizophrenia in the Japanese population. J Neural Transm 115: 1457-1461.
158. Kitagawa H, Takenouchi T, Azuma R, Wesnes K, Kramer W, Clody D et al (2003). Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology 28: 542-551.
159. Klein C, Andersen B (1991). On the influence of smoking upon smooth pursuit eye movements of schizophrenics and normal controls. J Psychophysiology 5: 361-369.
160. Kozak R, Bruno JP, Sarter M (2006). Augmented prefrontal acetylcholine release during challenged attentional performance. Cereb Cortex 16: 9-17. (Pubitemid 41746726)
161. Krystal JH, Anand A, Moghaddam B (2002). Effects of NMDA receptor antagonists: implications for the pathophysiology of schizophrenia. Arch Gen Psychiatry 59: 663-664. (Pubitemid 34747249)
162. Kuehn BM (2008). FDA warns of adverse events linked to smoking cessation drug and antiepileptics. JAMA 299: 1121-1122. (Pubitemid 351398444)
163. Lagostena C, Trocme-Thibierge P, Morain E, Cherubini E (2008). The partial alpha7 nicotine acetylcholine receptor agonist S 24795 enhances long-term potentiation at CA3-CA1 synapses in the adult mouse hippocampus. Neuropharmacology 54: 676-685.
164. Langmead CJ, Austin NE, Branch CL, Brown JT, Buchanan KA, Davies CH et al (2008). Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1. Br J Pharmacol 54: 1104-1115. (Pubitemid 351915055)
165. Langmead CJ, Fry VA, Forbes IT, Branch CL, Christopoulos A, Wood MD et al (2006). Probing the molecular mechanism of interaction between 4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the muscarinic M1 receptor: direct pharmacological evidence that AC-42 is an allosteric agonist. Mol Pharmacol 69: 236-246. (Pubitemid 43048910)
166. Lazareno S, Dolezal V, Popham A, Birdsall NJM (2004). Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: receptor subtype selectivity via cooperativity rather than affinity. J Pharmacol Exp Ther 65: 257-266. (Pubitemid 38113908)
167. Leach K, Loiacono RE, Felder CC, McKinzie DL, Mogg A, Shaw DB et al (2010). Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties. Neuropsychopharmacology 35: 855-869.
168. Lebois EP, Bridges TM, Lewis LM, Dawson ES, Kane AS, Xiang Z et al (2010). Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M1 receptor function in the central nervous system. ACS Chem Neurosci 1: 104-121.
169. Leonard S, Gault J, Adams C, Breese CR, Rollins Y, Adler LE et al (1998). Nicotinic receptors, smoking and schizophrenia. Restor Neurol Neurosci 12: 195-201. (Pubitemid 28368301)
170. Leonard S, Gault J, Hopkins J, Logel J, Vianzon R, Short M et al (2002). Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. Arch Gen Psychiatry 59: 1085-1096. (Pubitemid 35424018)
171. Leucht S, Busch R, Hamann J, Kissling W, Kane JM (2005). Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry 57: 1543-1549. (Pubitemid 40805384)
172. Levey AI, Edmunds SM, Heilman CJ, Desmond TJ, Frey KA (1994). Localization of muscarinic m3 receptor protein and M3 receptor binding in rat brain. Neuroscience 63: 207-221. (Pubitemid 24333962)
173. Levey AI, Edmunds SM, Hersch SM, Wiley RG, Heilman CJ (1995a). A light and electron microscopic study of m2 muscarinic acetylcholine receptor in the basal forebrain of the rat. J Comp Neurol 351: 339-356.
174. Levey AI, Edmunds SM, Koliatsos V, Wiley RG, Heilman CJ (1995b). Expression of ml-m4 muscarinic acetylcholine receptor proteins in rat hippocampus and regulation by cholinergic innervation. J Neurosci 15: 4077-4092.
175. Levey AI, Kitt CA, Simonds WF, Price DL, Brann MR (1991). Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtypespecific antibodies. J Neurosci 11: 3218-3226.
176. Levin ED (1992). Nicotinic systems and cognitive function. Psychopharmacology 108: 417-431.
177. Levin ED (2002). Nicotinic receptor subtypes and cognitive function. J Neurobiol 53: 633-640. (Pubitemid 35375592)
178. Levin ED, Bettegowda C, Blosser J, Gordon J (1999). AR-R17779, and alpha7 nicotinic agonist, improves learning and memory in rats. Behave Pharmacol 10: 675-680. (Pubitemid 30026062)
179. Levin ED, Briggs SJ, Christopher NC, Rose JE (1992). Persistence of chronic nicotine-induced cognitive facilitation. Behav Neural Biol 58: 152-158.
180. Levin ED, Christopher NC, Briggs SJ (1997). Chronic nicotinic agonist and antagonist effects on T-maze alternation. Physiol Behav 61: 863-866. (Pubitemid 27237174)
181. Levin ED, Conners CK, Silva D, Hinton SC, Meck WH, March J et al (1998). Transdermal nicotine effects on attention. Psychopharmacology (Berl) 140: 135-141. (Pubitemid 28538472)
182. Levin ED, McClernon FJ, Rezvani AH (2006). Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology 184: 523-539. (Pubitemid 43255869)
183. Lewis DA, Moghaddam B (2006). Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. Arch Neurol 63: 1372-1376. (Pubitemid 44547546)
184. Li X, Rainnie DG, McCarley RW, Greene RW (1998). Presynaptic nicotinic receptors facilitate monoaminergic transmission. J. Neurosci 18: 1904-1912. (Pubitemid 28103098)
185. Li Z, Bonhaus DW, Huang M, Prus AJ, Dai J, Meltzer HY (2007). AC260584 (4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one), a selective muscarinic M1 receptor agonist, increases acetylcholine and dopamine release in rat medial prefrontal cortex and hippocampus. Eur J Pharmacol 572: 129-137. (Pubitemid 47429641)
186. Liao CF, Themmen APN, Joho R, Barberis C, Birnbaumer M, Birnbaumer L (1989). Molecular cloning and expression of a fifth muscarinic acetylcholine receptor. J Biol Chem 264: 7328-7337. (Pubitemid 19119142)
187. Liao DL, Hong CJ, Chen HM, Chen YE, Lee SM, Chang CYet al (2003). Association of muscarinic m1 receptor genetic polymorphisms with psychiatric symptoms and cognitive function in schizophrenic patients. Neuropsychobiology 48: 72-76.
188. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, et al, HGDH Study Group (2003). Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine vs haloperidol. Am J Psychiatry 160: 1396-1404. (Pubitemid 41070913)
189. Lin NH, Gunn DE, Ryther KB, Garvey DS, Donnelly-Roberts DL, Decker MW et al (1997). Structure-activity studies on 2-methyl-3-(2(S)-pyrrolidinylmethoxy) pyridine (ABT-089): an orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing properties. J Med Chem 40: 385-390. (Pubitemid 27081974)
190. Lohr JB, Flynn K (1992). Smoking and schizophrenia. Schizophr Res 8: 93-102.
191. Luo S, Kulak JM, Cartier GE, Jacobsen RB, Yoshikami D, Olivera BM et al (1998). Alpha-conotoxin AuIB selectively blocks alpha3 beta4 nicotinic acetylcholine receptors and nicotine-evoked norepinephrine release. J Neurosci 18: 8571-8579. (Pubitemid 28491724)
192. Ma L, Seager MA, Wittmann M, Jacobson M, Bickel D, Burno M et al (2009). Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation. Proc Natl Acad Sci USA 106: 15950-15955.
193. Malysz J, Gr̈nlien JH, Timmermann DB, Hakerud M, Thorin-Hagene K, Ween H et al (2009). Evaluation of alpha7 nicotinic acetylcholine receptor agonists and positive allosteric modulators using the parallel oocyte electrophysiology test station. Assay Drug Dev Technol 7: 374-390.
194. Mancama D, Arranz MJ, Landau S, Kerwin R (2003). Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 119B: 2-6. (Pubitemid 37064044)
195. Mann EO, Greenfield SA (2003). Novel modulatory mechanisms revealed by the sustained application of nicotine in the guinea-pig hippocampus in vitro. J Physiol 551: 539-550. (Pubitemid 37121711)
196. Mansvelder HD, Keath JR, McGehee DS (2002). Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas. Neuron 33: 905-919. (Pubitemid 34246356)
197. Mansvelder HD, McGehee DS (2000). Long-term potentiation of excitatory inputs to brain reward areas by nicotine. Neuron 27: 349-357.
198. Marino MJ, Rouse ST, Levey AI, Potter LT, Conn PJ (1998). Activation of the genetically defined m1 muscarinic receptor potentiates N-methyl-D-aspartate (NMDA) receptor currents in hippocampal pyramidal cells. Proc Natl Acad Sci USA 95: 11465-11470. (Pubitemid 28450152)
199. Marlo JE, Niswender CM, Days EL, Bridges TM, Xiang Y, Rodriguez AL et al (2009). Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity. Mol Pharmacol 75: 577-588.
200. Martin-Ruiz CM, Haroutunian VH, Long P, Young AH, Davis KL, Perry EK et al (2003). Dementia rating and nicotinic receptor expression in the prefrontal cortex in schizophrenia. Biol Psychiatry 54: 1222-1233. (Pubitemid 37464868)
201. Marubio LM, del Mar Arroyo-Jimenez M, Cordero-Erausquin M, Léna C, Le Novère N, de Kerchove d'Exaerde A et al (1999). Reduced antinociception in mice lacking neuronal nicotinic receptor subunits. Nature 398: 805-810.
202. Marutle A, Zhang X, Court J, Piggott M, Johnson M, Perry R et al (2001). Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia. J Chem Neuroanat 22: 115-126. (Pubitemid 32695514)
203. Matsuoka N, Maeda N, Ohkubo Y, Yamaguchi I (1991). Differential effects of physostigmine and pilocarpine on the spatial memory deficits produced by two septo-hippocampal deafferentations in rats. Brain Res 559: 233-240.
204. McDermott BE, Sautter FJ, Garver DL (1991). Heterogeneity of schizophrenia: relationship to latency of neuroleptic response. Psychiatry Res 37: 97-103.
205. McGeer PL, McGeer EG (1977). Possible changes in striatal and limbic cholinergic systems in schizophrenia. Arch Gen Psychiatry 34: 1319-1323. (Pubitemid 8240621)
206. McQuiston AR, Madison DV (1999). Nicotinic receptor activation excites distinct subtypes of interneurons in the rat hippocampus. J Neurosci 19: 2887-2896. (Pubitemid 29173985)
207. Mesulam MM, Mufson EJ, Wainer BH, Levey AI (1983). Central cholinergic pathways in the rat: an overview based on an alternative nomenclature (Ch1-Ch6). Neuroscience 10: 1185-1201. (Pubitemid 14178569)
208. Mexal S, Berger R, Logel J, Ross RG, Freedman R, Leonard S (2010). Differential regulation of alpha7 nicotinic receptor gene (CHRNA7) expression in schizophrenic smokers. J Mol Neurosci 40: 185-195.
209. Migeon JC, Thomas SL, Nathanson NM (1995). Differential coupling of m2 and m4 muscarinic receptors to inhibition of adenylyl cyclase by Gi alpha and G(o)alpha subunits. J Biol Chem 270: 16070-16074.
210. Mihalak KB, Carroll FI, Luetje CW (2006). Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol 70: 801-805. (Pubitemid 44268437)
211. Miyakawa T, Yamada M, Duttaroy A, Wess J (2001). Hyperactivity and intact hippocampus-dependent learning in mice lacking the M1 muscarinic acetylcholine receptor. J Neurosci 21: 5239-5250. (Pubitemid 32622949)
212. Moran PM (1993). Differential effects of scopolamine and mecamylamine on working and reference memory in the rat. Pharmacol Biochem Behav 45: 533-538.
213. Mukhin AG, Gündisch D, Horti AG, Koren AO, Tamagnan G, Kimes AS et al (2000). 5-Iodo-A-85380, an alpha4beta2 subtype-selective ligand for nicotinic acetylcholine receptors. Mol Pharmacol 57: 642-649. (Pubitemid 30140897)
214. Mulle C, Vidal C, Benoit P, Changeux JP (1991). Existence of different subtypes of nicotinic acetylcholine receptors in the rat habenulo- interpeduncular system. J Neurosci 11: 2588-2597.
215. Mullen G, Napier J, Balestra M, DeCory T, Hale G, Macor J et al (2000). Spiro[1-azabicyclo[2.2.2]octane-3,50-oxazolidin-20-one], a conformationally restricted analogue of acetylcholine, is a highly selective full agonist at the alpha 7 nicotinic acetylcholine receptor. J Med Chem 43: 4045-4050.
216. Nanri M, Kasahara N, Yamamoto J, Miyake H, Watanabe H (1998). A comparative study on the effects of nicotine and GTS-21, a new nicotinic agonist, on the locomotor activity and brain monoamine level. Jpn J Pharmacol 78: 385-389. (Pubitemid 28554207)
217. Natesan S, Reckless GE, Barlow KB, Nobrega JN, Kapur S (2007). Evaluation of N-desmethylclozapine as a potential antipsychoticFpreclinical studies. Neuropsychopharmacology 32: 1540-1549. (Pubitemid 46920156)
218. Nawaratne V, Leach K, Felder CC, Sexton PM, Christopoulos A (2010). Structural determinants of allosteric agonism and modulation at the M4 muscarinic acetylcholine receptor: identification of ligand-specific and global activation mechanisms. J Biol Chem 285: 19012-19021.
219. Newhouse PA, Potter A, Corwin J, Lenox R (1992). Acute nicotinic blockade produces cognitive impairment in normal humans. Psychopharmacology 108: 480-484.
220. Newhouse PA, Potter A, Corwin J, Lenox R (1994). Age-related effects of the nicotinic antagonist mecamylamine on cognition and behavior. Neuropsychopharmacology 10: 93-107. (Pubitemid 24152360)
221. Newhouse PA, Potter A, Singh A (2004). Effects of nicotinic stimulation on cognitive performance. Curr Opin Pharmacol 4: 36-46. (Pubitemid 38145836)
222. Ng HJ, Whittemore ER, Tran MB, Hogenkamp DJ, Broide RS, Johnstone TB et al (2007). Nootropic alpha7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators. Proc Natl Acad Sci USA 104: 8059-8064. (Pubitemid 47185875)
223. Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK (2004). Identification of separable cognitive factors in schizophrenia. Schizophr Res 72: 29-39. (Pubitemid 39452903)
224. Obinu MC, Reibaud M, Miquet JM, Pasquet M, Rooney T (2002). Brain-selective stimulation of nicotinic receptors by TC-1734 enhances ACh transmission from frontoparietal cortex and memory in rodents. Prog Neuropsychopharmacol Biol Psychiatry 26: 913-918. (Pubitemid 35245559)
225. Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D et al (2006). Proof-of-concept trial of an alpha nicotinic agonist in schizophrenia. Arch Gen Psychiatry 63: 630-638. (Pubitemid 43848294)
226. Orr-Urtreger A, Göldner FM, Saeki M, Lorenzo I, Goldberg L, De Biasi M et al (1997). Mice deficient in the alpha7 neuronal nicotinic acetylcholine receptor lack alphabungarotoxin binding sites and hippocampal fast nicotinic currents. J Neurosci 17: 9165-9171. (Pubitemid 27498444)
227. Osterholm RK, Camoriano JK (1982). Transdermal scopolamine psychosis. JAMA 247: 3081. (Pubitemid 12114458)
228. Palma E, Bertrand S, Binzoni T, Bertrand D (1996). Neuronal nicotinic alpha 7 receptor expressed in Xenopus oocytes presents five putative binding sites for methyllycaconitine. J Physiol 491: 151-161.
229. Parsons B, Allison DB, Loebel A, Williams K, Giller E, Romano S et al (2009). Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res 110: 103-110.
230. Paylor R, Nguyen M, Crawley JN, Patrick J, Beaudet A, Orr-Urtreger A (1998). Alpha7 nicotinic receptor subunits are not necessary for hippocampaldependent learning or sensorimotor gating: a behavioral characterization of Acra7-deficient mice. Learn Membr 5: 302-316. (Pubitemid 29115261)
231. Pazzagli A, Pepeu G (1965). Amnesic properties of scopolamine and brain acetylcholine in the rat. Int J Neuropharmacol 4: 291-299.
232. Perry DC, Xiao Y, Nguyen HN, Musachio JL, Dávila-Garća MI, Kellar KJ (2002). Measuring nicotinic receptors with characteristics of alpha4beta2, alpha3beta2 and alpha3beta4 subtypes in rat tissues by autoradiography. J Neurochem 82: 468-481. (Pubitemid 34831488)
233. Perry KW, Nisenbaum LK, George CA, Shannon HE, Felder CC, Bymaster FP (2001). The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex. Biol Psychiatry 49: 716-725. (Pubitemid 32328121)
234. Pfeiffer CC, Jenny EH (1957). The inhibition of the conditioned response and the counteraction of schizophrenia by muscarinic stimulation of the brain. Ann NY Acad Sci 66: 753-764.
235. Phelps PE, Houser CR, Vaughn JE (1985). Immunocytochemical localization of choline acetyltransferase within the rat neostriatum: a correlated light and electron microscopic study of cholinergic neurons and synapses. J Comp Neurol 238: 286-307. (Pubitemid 16241700)
236. Picciotto MR, Addy NA, Mineur YS, Brunzell DH (2008). It is not 'either/or': activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood. Prog Neurobiol 84: 329-342.
237. Pichat P, Bergis OE, Terranova JP, Urani A, Duarte C, Santucci V et al (2007). SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacology 32: 17-34. (Pubitemid 44967781)
238. Poulin B, Butcher A, McWilliams P, Bourgognon JM, Pawlak R, Kong KC et al (2010). The M3-muscarinic receptor regulates learning and memory in a receptor phosphorylation/arrestin-dependent manner. Proc Natl Acad Sci USA 107: 9440-9445.
239. Powchik P, Davidson M, Haroutunian V, Gabriel SM, Purohit DP, Perl DP et al (1998). Postmortem studies in schizophrenia. Schizophr Bull 24: 325-341. (Pubitemid 28378220)
240. Prendergast MA, Jackson WJ, Terry Jr AV, Decker MW, Arneric SP, Buccafusco JJ (1998). Central nicotinic receptor agonists ABT-418, ABT-089, and (f)-nicotine reduce distractibility in adult monkeys. Psychopharmacology 136: 50-58.
241. Prendergast MA, Terry Jr AV, Jackson WJ, Marsh KC, Decker MW, Arneric SP et al (1997). Improvement in accuracy of delayed recall in aged and non-aged, mature monkeys after intramuscular or transdermal administration of the CNS nicotinic receptor agonist ABT-418. Psychopharmacology 130: 276-284. (Pubitemid 27170361)
242. Quirion R, Richard J, Wilson A (1994). Muscarinic and nicotinic modulation of cortical acetylcholine release monitored by in vivo microdialysis in freely moving adult rats. Synapse 17: 92-100. (Pubitemid 24168200)
243. Rabin RA, Sacco KA, George TP (2009). Correlation of prepulse inhibition and Wisconsin Card Sorting Test in schizophrenia and controls: effects of smoking status. Schizophr Res 114: 91-97.
244. Radek RJ, Kohlhaas KL, Rueter LE, Mohler EG (2010). Treating the cognitive deficits of schizophrenia with alpha4beta2 neuronal nicotinic receptor agonists. Curr Pharm Des 16: 309-322.
245. Raedler TJ, Knable MB, Jones DW, Urbina RA, Gorey JG, Lee KS et al (2003). In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am J Psychiatry 160: 118-127. (Pubitemid 36042435)
246. Raedler TJ, Schreiner A, Naber D, Wiedemann K (2007). Early onset of treatment effects with oral risperidone. BMC Psychiatry 7: 4.
247. Redrobe JP, Nielsen EØ, Christensen JK, Peters D, Timmermann DB, Olsen GM (2009). Alpha7 nicotinic acetylcholine receptor activation ameliorates scopolamine-induced behavioural changes in a modified continuous Y-maze task in mice. Eur J Pharmacol 602: 58-65.
248. Rezvani AH, Kholdebarin E, Brucato FH, Callahan PM, Lowe DA, Levin ED (2009). Effect of R3487/MEM3454, a novel nicotinic alpha7 receptor partial agonist and 5-HT3 antagonist on sustained attention in rats. Prog Neuropsychopharmacol Biol Psychiatry 33: 269-275.
249. Rezvani AH, Levin ED (2001). Cognitive effects of nicotine. Biol Psychiatry 49: 258-267. (Pubitemid 32178435)
250. Roncarati R, Scali C, Comery TA, Grauer SM, Aschmi S, Bothmann H et al (2009). Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders. J Pharmacol Exp Ther 329: 459-468.
251. Ropert N, KrnjevićK (1982). Pharmacological characteristics of facilitation of hippocampal population spikes by cholinomimetics. Neuroscience 7: 1963-1977. (Pubitemid 12047339)
252. Rouse ST, Edmunds SM, Yi H, Gilmor ML, Levey AI (2000). Localization of M(2) muscarinic acetylcholine receptor protein in cholinergic and non-cholinergic terminals in rat hippocampus. Neurosci Lett 284: 182-186. (Pubitemid 30204543)
253. Rouse ST, Gilmor ML, Levey AI (1998). Differential presynaptic and postsynaptic expression of ml-m4 muscarinic acetylcholine receptors at the perforant pathway/granule cell synapse. Neuroscience 86: 221-232. (Pubitemid 28270868)
254. Rouse ST, Marino MJ, Potter LT, Conn PJ, Levey AI (1999). Muscarinic receptor subtypes involved in hippocampal circuits. Life Sci 64: 501-509. (Pubitemid 29066699)
255. Rupniak NM, Steventon MJ, Field MJ, Jennings CA, Iversen SD (1989). Comparison of the effects of four cholinomimetic agents on cognition in primates following disruption by scopolamine or by lists of objects. Psychopharmacology 99: 189-195. (Pubitemid 19215216)
256. Rusted JM, Warburton DM (1988). The effects of scopolamine on working memory in healthy young volunteers. Psychopharmacology 96: 145-152.
257. Sacco KA, Termine A, Dudas MM, Seyal AA, Allen TM, Vessicchio JC et al (2006). Neuropsychological deficits in nonsmokers with schizophrenia: effects of a nicotinic antagonist. Schizophr Res 85: 213-221. (Pubitemid 43947531)
258. Sacco KA, Termine A, Seyal A, Dudas MM, Vessicchio JC, Krishnan-Sarin S et al (2005). Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. Arch Gen Psychiatry 62: 649-659. (Pubitemid 40973440)
259. Sarter M, Parikh V, Howe WM (2009). nAChR agonist-induced cognition enhancement: integration of cognitive and neuronal mechanisms. Biochem Pharmacol 78: 658-667.
260. Satoh K, Fibiger HC (1986). Cholinergic neurons of the laterodorsal tegmental nucleus: efferent and afferent connections. J Comp Neurol 253: 277-302. (Pubitemid 17181056)
261. Scarr E, Cowie TF, Kanellakis S, Sundram S, Pantelis C, Dean B (2009). Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia. Mol Psychiatry 14: 1017-1023.
262. Schoepfer R, Conroy WG, Whiting P, Gore M, Lindstrom J (1990). Brain alphabungarotoxin binding protein cDNAs and MAbs reveal subtypes of this branch of the ligand-gated ion channel gene superfamily. Neuron 5: 35-48. (Pubitemid 20224498)
263. Seeger T, Fedorova I, Zheng F, Miyakawa T, Koustova E, Gomeza J et al (2004). M2 muscarinic acetylcholine receptor knock-out mice show deficits in behavioral flexibility, working memory, and hippocampal plasticity. J Neurosci 24: !QJ;10117-10127. (Pubitemid 39492037)
264. Seguela P, Wadiche J, Dineley-Miller K, Dani JA, Patrick JW (1993). Molecular cloning, functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable to calcium. J Neurosci 13: 596-604. (Pubitemid 23045143)
265. Severance EG, Yolken RH (2008). Novel alpha7 nicotinic receptor isoforms and deficient cholinergic transcription in schizophrenia. Genes Brain Behav 7: 37-45.
266. Shannon HE, Rasmussen K, Bymaster FP, Hart JC, Peters SC, Swedberg MD et al (2000). Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice. Schizophr Res 42: 249-259. (Pubitemid 30216536)
267. Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dubé S, Mallinckrodt C et al (2008). Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry 165: 1033-1039.
268. Sher E, Chen Y, Sharples TJ, Broad LM, Benedetti G, Zwart R et al (2004). Physiological roles of neuronal nicotinic receptor subtypes: new insights on the nicotinic modulation of neurotransmitter release, synaptic transmission and plasticity. Curr Top Med Chem 4: 283-297. (Pubitemid 38842572)
269. Shirey JK, Brady AE, Jones PJ, Davis AA, Bridges TM, Kennedy JP et al (2009). A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning. J Neurosci 29: 14271-14286.
270. Shirey JK, Xiang Z, Orton D, Brady AE, Johnson KA, Williams R et al (2008). An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission. Nat Chem Biol 4: 42-50. (Pubitemid 350273654)
271. Simosky JK, Stevens KE, Kem WR, Freedman R (2001). Intragastric DMXB-A, an alpha7 nicotinic agonist, improves deficient sensory inhibition in DBA/2 mice. Biol Psychiatry 50: 493-500. (Pubitemid 32971880)
272. Siok CJ, Rogers JA, Kocsis B, Hajos M (2006). Activation of alpha7 acetylcholine receptors augments stimulation-induced hippocampal theta oscillation. Eur J Neurosci 23: 570-574.
273. Smith RC, Lindenmayer JP, Davis JM, Cornwell J, Noth K, Gupta S et al (2009). Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder. Schizophr Res 110: 149-155.
274. Smith RC, Warner-Cohen J, Matute M, Butler E, Kelly E, Vaidhyanathaswamy S et al (2006). Effects of nicotine nasal spray on cognitive function in schizophrenia. Neuropsychopharmacology 31: 637-643. (Pubitemid 43276979)
275. Söderman A, Mikkelsen JD, West MJ, Christensen DZ, Jensen MS (2011). Activation of nicotinic a(7) acetylcholine receptor enhances long term potentation in wild type mice but not in APP(swe)/PS1DE9 mice. Neurosci Lett 487: 325-329.
276. Soliakov L, Gallagher T, Wonnacott S (1995). Anatoxin-a-evoked [3H]dopamine release from rat striatal synaptosomes. Neuropharmacology 34: 1535-1541.
277. Soliakov L, Wonnacott S (1996). Voltage-sensitive Ca2+ channels involved in nicotinic receptor-mediated [3H]dopamine release from rat striatal synaptosomes. J Neurochem 67: 163-170.
278. Sood A, Beach JW, Webster SJ, Terry Jr AV, Buccafusco JJ (2007). The effects of JWB 1-84-1 on memory-related task performance by amyloid Ab transgenic mice and aged Rhesus monkeys. Neuropharmacology 53: 588-600. (Pubitemid 47513166)
279. Spalding TA, Trotter C, Skjaerbaek N, Messier TL, Currier EA, Burstein ES et al (2002). Discovery of an ectopic activation site on the M(l) muscarinic receptor. Mol Pharmacol 61: 1297-1302. (Pubitemid 34575739)
280. Spencer JP, Middleton LJ, Davies CH (2010). Investigation into the efficacy of the acetylcholinesterase inhibitor, donepezil, and novel procognitive agents to induce gamma oscillations in rat hippocampal slices. Neuropharmacology 59: 437-443.
281. Stanhope KJ, Mirza NR, Bickerdike MJ, Bright JL, Harrington NR, Hesselink MB et al (2001). The muscarinic receptor agonist xanomeline has an antipsychoticlike profile in the rat. J Pharmacol Exp Ther 299: 782-792.
282. Stassen HH, Bridler R, Hägele S, Hergersberg M, Mehmann B, Schinzel A et al (2000). Schizophrenia and smoking: evidence for a common neurobiological basis? Am J Med Genet 96: 173-177. (Pubitemid 30180858)
283. Stefansson H, Rujescu D, Cichon S, Pietiläinen OP, Ingason A, Steinberg S et al (2008). Large recurrent microdeletions associated with schizophrenia. Nature 455: 232-236.
284. Stevens KE, Freedman R, Collins AC, Hall M, Leonard S, Marks MJ et al (1996). Genetic correlation of inhibitory gating of hippocampal auditory evoked response and alpha-bungarotoxin-binding nicotinic cholinergic receptors in inbred mouse strains. Neuropsychopharmacology 15: 152-162. (Pubitemid 26255162)
285. Stevens KE, Kem WR, Mahnir VM, Freedman R (1998). Selective alpha7-nicotinic agonists normalize inhibition of auditory response in DBA mice. Psychopharmacology 136: 320-327. (Pubitemid 28189660)
286. Stevens KE, Wear KD (1997). Normalizing effects of nicotine and a novel nicotinic agonist on hippocampal auditory gating in two animal models. Pharmacol Biochem Behav 57: 869-874. (Pubitemid 27334438)
287. Stevens KE, Cornejo B, Adams CE, Zheng L, Yonchek J, Hoffman KL et al (2010). Continuous administration of a selective alpha7 nicotinic partial agonist, DMXBA, improves sensory inhibition without causing tachyphylaxis or receptor upregulation in DBA/2 mice. Brain Res 1352: 140-146.
288. Steidl S, Yeomans JS (2009). M5 muscarinic receptor knockout mice show reduced morphine-induced locomotion but increased locomotion after cholinergic antagonism in the ventral tegmental area. J Pharmacol Exp Ther 328: 263-275.
289. Sur C, Mallorga PJ, Wittmann M, Jacobson MA, Pascarella D, Williams JB et al (2003). N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc Natl Acad Sci USA 100: 13674-13679. (Pubitemid 37444798)
290. Swartz MS, Stroup TS, McEvoy JP, Davis SM, Rosenheck RA, Keefe RS et al (2008). What CATIE found: results from the schizophrenia trial. Psychiatry Serv 59: 500-506.
291. Sydserff S, Sutton EJ, Song D, Quirk MC, Maciag C, Li C et al (2009). Selective alpha7 nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processes. Biochem Pharmacol 78: 880-888.
292. Tandon R, Shipley JE, Greden JF, Mann NA, Eisner WH, Goodson J (1991). Muscarinic cholinergic hyperactivity in schizophrenia. Relationship to positive and negative symptoms. Schizophr Res 4: 23-30.
293. Tapia L, Kuryatov A, Lindstrom J (2007). Ca2+ permeability of the (alpha4)3(beta2)2 stoichiometry greatly exceeds that of (alpha4)2(beta2)3 human acetylcholine receptors. Mol Pharmacol 71: 769-776.
294. Terry Jr AV, Buccafusco JJ, Jackson WJ, Zagrodnik S, Evans-Martin FF, Decker MW (1996). Effects of stimulation or blockade of central nicotinic-cholinergic receptors on performance of a novel version of the rat stimulus discrimination task. Psychopharmacology 123: 172-181. (Pubitemid 26041915)
295. Terry Jr AV, Buccafusco JJ, Prendergast MA (1999). Dose-specific improvements in memory-related task performance by rats and aged monkeys administered the nicotinic-cholinergic antagonist mecamylamine. Drug Dev Res 47: 127-136. (Pubitemid 29400329)
296. Thomsen M, Woldbye DP, Woertwein G, Fink-Jensen A, Wess J, Caine SB (2005). Reduced cocaine self-administration in muscarinic M5 acetylcholine receptordeficient mice. Neuropsychopharmacology 30: S88-S88.
297. Thomsen M, Wörtwein G, Fink-Jensen A, Woldbye DP, Wess J, Caine SB (2007). Decreased prepulse inhibition and increased sensitivity to muscarinic, but not dopaminergic drugs in M5 muscarinic acetylcholine receptor knockout mice. Psychopharmacology (Berl) 192: 97-110. (Pubitemid 46673887)
298. Thomsen MS, Christensen DZ, Hansen HH, Redrobe JP, Mikkelsen JD (2009). Alpha(7) nicotinic acetylcholine receptor activation prevents behavioral and molecular changes induced by repeated phencyclidine treatment. Neuropharmacology 56: 1001-1009.
299. Thomsen MS, Hay-Schmidt A, Hansen HH, Mikkelsen JD (2010). Distinct neural pathways mediate a7 nicotinic acetylcholine receptor-dependent activation of the forebrain. Cereb Cortex 20: 2092-2102.
300. Timmermann DB, Gr̈nlien JH, Kohlhaas KL, Nielsen EØ, Dam E, Jrgensen TD et al (2007). An allosteric modulator of the alpha7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo. J Pharmacol Exp Ther 323: 294-307. (Pubitemid 47443280)
301. Tregellas JR, Olincy A, Johnson L, Tanabe J, Shatti S, Martin LF et al (2010). Functional magnetic resonance imaging of effects of a nicotinic agonist in schizophrenia. Neuropsychopharmacology 35: 938-942.
302. Tregellas JR, Tanabe J, Rojas DC, Shatti S, Olincy A, Johnson L et al (2011). Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia. Biol Psychiatry 69: 7-11.
303. Tsai G, Coyle JT (2002). Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 42: 165-179. (Pubitemid 34160524)
304. Tzavara ET, Bymaster FP, Davis RJ, Wade MR, Perry KW, Wess J et al (2004). M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related CNS pathologies. FASEB J 18: 1410-1412. (Pubitemid 39561597)
305. Tzavara ET, Bymaster FP, Felder CC, Wade M, Gomeza J, Wess J et al (2003). Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4 and M2/M4 muscarinic receptor knockout mice. Mol Psychiatry 8: 673-679. (Pubitemid 36980624)
306. Van Kampen M, Selbach K, Schneider R, Schiegel E, Boess F, Schreiber R (2004). AR-R 17779 improves social recognition in rats by activation of nicotinic alpha7 receptors. Psychopharmacology 172: 375-383. (Pubitemid 38650972)
307. Vanover KE, Veinbergs I, Davis RE (2008). Antipsychotic-like behavioral effects and cognitive enhancement by a potent and selective muscarinic M-sub-1 receptor agonist, AC-260584. Behav Neurosci 122: 570-575. (Pubitemid 351787835)
308. Vicens P, Ribes D, Torrente M, Domingo JL. (2011). Behavioral effects of PNU-282987, an alpha7 nicotinic receptor agonist, in mic. Behav Brain Res 216: 341-348.
309. Vilaro MT, Palacios JM, Mengod G (1990). Localization of m5 muscarinic receptor mRNA in rat brain examined by in situ hybridization histochemistry. Neurosci Lett 114: 154-159. (Pubitemid 20188950)
310. Waldo MC, Woodward L, Adler LE (2010). Varenicline and P50 auditory gating in medicated schizophrenic patients: a pilot study. Psychiatry Res 175: 179-180.
311. Wallace TL, Callahan PM, Tehim A, Bertrand D, Tombaugh G, Wang S et al (2011). RG3487, a novel nicotinic a7 receptor partial agonist, improves cognition and sensorimotor gating in rodents. J Pharmacol Exp Ther 336: 242-253.
312. Weiner DM, Levey AI, Brann MR (1990). Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basal ganglia. Proc Natl Acad Sci USA 87: 7050-7054.
313. Wess J, Eglen RM, Gautam D (2007). Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat Rev Drug Discov 6: 721-733. (Pubitemid 47342315)
314. Wildeboer KM, Stevens KE (2008). Stimulation of the alpha4beta2 nicotinic receptor by 5-I A-85380 improves auditory gating in DBA/2 mice. Brain Res 1224: 29-36.
315. Wishka DG, Walker DP, Yates KM, Reitz SC, Jia S, Myers JK et al (2006). Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5- carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structureFactivity relationship. J Med Chem 49: 4425-4436. (Pubitemid 44036685)
316. Wonnacott S (1997). Presynaptic nicotinic ACh receptors. Trends Neurosci 20: 92-98. (Pubitemid 27050704)
317. Wonnacott S, Kaiser S, Mogg A, Soliakov L, Jones IW (2000). Presynaptic nicotinic receptors modulating dopamine release in the rat striatum. Eur J Pharmacol 393: 51-58. (Pubitemid 30193400)
318. Woznica AA, Sacco KA, George TP (2009). Prepulse inhibition deficits in schizophrenia are modified by smoking status. Schizophr Res 112: 86-90.
319. Xiao Y, Fan H, Musachio JL, Wei ZL, Chellappan SK, Kozikowski AP et al (2006). Sazetidine-A, a novel ligand that desensitizes a4b2 nicotinic acetylcholine receptors without activating them. Mol Pharmacol 70: 1454-1460. (Pubitemid 44435998)
320. Yamada M, Basile AS, Fedorova I, Zhang W, Duttaroy A, Cui Y et al (2003). Novel insights into M5 muscarinic acetylcholine receptor function by the use of gene targeting technology. Life Sci 74: 345-353. (Pubitemid 37357065)
321. Yamada M, Lamping KG, Duttaroy A, Zhang W, Cui Y, Bymaster FP et al (2001a). Cholinergic dilation of cerebral blood vessels is abolished in M5 muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci USA 98: 14096-14101. (Pubitemid 33116030)
322. Yamada M, Miyakawa T, Duttaroy A, Yamanaka A, Moriguchi T, Makita R et al (2001b). Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean. Nature 410: 207-212. (Pubitemid 32216592)
323. Young CD, Meltzer HY, Deutch AY (1998). Effects of desmethylclozapine on Fos protein expression in the forebrain: in vivo biological activity of the clozapine metabolite. Neuropsychopharmacology 19: 99-103. (Pubitemid 28255219)
324. Zang Z, Creese I (1997). Differential regulation of expression of rat hippocampal muscarinic receptor subtypes following fimbria-fornix lesion. Biochem Pharmacol 53: 1379-1382. (Pubitemid 27305638)
325. Zhang W, Basile AS, Gomeza J, Volpicelli LA, Levey AI, Wess J (2002). Characterization of central inhibitory muscarinic autoreceptors by the use of muscarinic acetylcholine receptor knockout mice. J Neurosci 22: 1709-1717. (Pubitemid 35386289)
326. Zavitsanou K, Katsifis A, Mattner F, Huang XF (2004). Investigation of m1/m4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder. Neuropsychopharmacology 29: 619-625.
327. Zoli M, Picciotto MR, Ferrari R, Cocchi D, Changeux JP (1999). Increased neurodegeneration during ageing in mice lacking high-affinity nicotine receptors. EMBO J 18: 1235-1244. (Pubitemid 29110308)